Investors Trading Alert: AstraZeneca PLC (AZN), Novo Nordisk A/S (NVO)

Adjust Comment Print

NVO's profit will be $1.66 billion for 17.20 P/E if the $0.69 EPS becomes a reality. Zero analysts have issued estimates for Novo Nordisk's earnings. The hedge fund held 64,200 shares of the oil & gas production company at the end of 2017Q4, valued at $686,000, down from 131,100 at the end of the previous reported quarter. (NASDAQ:MAR). Evermay Wealth Management Ltd reported 5,141 shares or 0.26% of all its holdings.

The consensus recommendation, according to Zacks Investment research, is 2.13. The stock increased 1.43% or $0.6699 during the last trading session, reaching $47.6099. Analysts sees 30.19 % EPS growth this quarter. Novo Nordisk had a net margin of 34.09% and a return on equity of 82.72%.

A number of research analysts have weighed in on the company.

Among 15 analysts covering Novo Nordisk (ADR) (NYSE:NVO), 7 have Buy rating, 0 Sell and 8 Hold. The company rating was maintained by Goldman Sachs on Friday, January 19. Morgan Stanley downgraded the stock to "Equal-Weight" rating in Thursday, September 1 report.

AstraZeneca PLC (AZN) analysts on average have given a price target of $38.89 on AZN stock. Now it had 6.87 million shares held by the institutional investor.

Frank Warren: Joshua not a 'true champ' until he beats Fury
WBO middleweight master Billy Joe Saunders recently shared a video of Fury sparring Mariusz Wach in Hatton's gym. The Manchester boxer is set to make his own return to boxing on June 9 against a now unnamed opponent.


Sustainable Growth Advisers Lp increased its stake in Novo Nordisk A/S (NVO) by 8.35% based on its latest 2017Q4 regulatory filing with the SEC. Fairfield Bush & CO. grew its holdings in Novo Nordisk by 5.9% during the fourth quarter. Finally, Lakeview Capital Partners LLC acquired a new stake in shares of Novo Nordisk in the 4th quarter worth $204,000.

Shares of NYSE NVO opened at $49.25 on Friday. The firm has a market capitalization of $118,682.16, a price-to-earnings ratio of 20.76, a P/E/G ratio of 2.38 and a beta of 0.67. Novo Nordisk (ADR) had 21 analyst reports since August 28, 2015 according to SRatingsIntel.

Total analysts of 6 have positions in Novo Nordisk A\/S Common Stock (NYSE:NVO) as follows: 4 rated it a "Buy", 0 with "Sell" and 2 with "Hold". Folketrygdfondet sold 345,000 shares as the company's stock declined 9.08% with the market. Shares buyback plans are usually a sign that the company's board believes its shares are undervalued.

The firm also recently declared a special dividend, which will be paid on Tuesday, April 3rd. Shareholders of record on Monday, March 26th were given a $0.8117 dividend. This represents a yield of 0.96%. The ex-dividend date of this dividend was Friday, March 23rd. Novo Nordisk Adr now has $114.62B valuation.

"TRADEMARK VIOLATION WARNING: "$0.69 Earnings Per Share Expected for Novo Nordisk (NVO) This Quarter" was published by registrarjournal.com and is owned by of registrarjournal.com. If you are accessing this report on another website, it was copied illegally and reposted in violation of USA and global copyright & trademark legislation. The company has a market cap of $91.51 Billion. It operates in two divisions, Diabetes and Obesity Care, and Biopharmaceuticals.18.69 is the P/E ratio.

Comments